{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:57:14Z","timestamp":1787011034028,"version":"build-2736575974"},"reference-count":81,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T00:00:00Z","timestamp":1752105600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Pfizer Canada"},{"name":"Eisai Canada"},{"name":"Amgen Canada"},{"name":"Astellas Pharma Canada"},{"name":"Incyte"},{"name":"Merck Canada"},{"name":"Taiho Pharmaceutical"},{"name":"Takeda Canada"},{"name":"Organon Biosciences"},{"name":"Bristol-Myers Squibb Canada"},{"name":"AstraZeneca Canada"},{"name":"Roche Canada"},{"name":"AbbVie"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>The 26th annual Western Canadian Gastrointestinal Cancer Consensus Conference (WCGCCC) was held in Saskatoon, Saskatchewan, on 17\u201318 October 2024. The WCGCCC is an interactive multidisciplinary conference that was attended by healthcare professionals from across Western Canada (British Columbia, Alberta, Saskatchewan, and Manitoba) who are involved in the care of patients with hepatocellular and biliary tract cancers. Specialists from the fields of medical and radiation oncology, interventional radiology, pathology and laboratory medicine, and general and hepatobiliary surgery participated in presentations and discussions for the purpose of developing the recommendations presented here. This consensus statement addresses current issues in the management of hepatocellular and biliary tract cancers.<\/jats:p>","DOI":"10.3390\/curroncol32070398","type":"journal-article","created":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T10:26:53Z","timestamp":1752229613000},"page":"398","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Report from the 26th Annual Western Canadian Gastrointestinal Cancer Consensus Conference on Hepatocellular and Biliary Tract Cancer, Saskatoon, Saskatchewan, 17\u201318 October 2024"],"prefix":"10.3390","volume":"32","author":[{"given":"Deepti","family":"Ravi","sequence":"first","affiliation":[{"name":"Saskatchewan Health Authority, Saskatoon, SK S7K 0M7, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2099-698X","authenticated-orcid":false,"given":"Shahid","family":"Ahmed","sequence":"additional","affiliation":[{"name":"Saskatoon Cancer Centre, Saskatoon, SK S7N 4H4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blaire","family":"Anderson","sequence":"additional","affiliation":[{"name":"College of Medicine, University of Alberta, Edmonton, AB T6G 2B7, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brady","family":"Anderson","sequence":"additional","affiliation":[{"name":"Western Manitoba Cancer Center, Brandon, MB R7A 5M8, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan","family":"Brunet","sequence":"additional","affiliation":[{"name":"Saskatoon Cancer Centre, Saskatoon, SK S7N 4H4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9388-150X","authenticated-orcid":false,"given":"Haji","family":"Chalchal","sequence":"additional","affiliation":[{"name":"Allan Blair Cancer Centre, Regina, SK S4T 7T1, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arun","family":"Elangovan","sequence":"additional","affiliation":[{"name":"Saskatoon Cancer Centre, Saskatoon, SK S7N 4H4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgia","family":"Geller","sequence":"additional","affiliation":[{"name":"BC Cancer Centre, Victoria, BC V8R 6V5, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vallerie","family":"Gordon","sequence":"additional","affiliation":[{"name":"Saskatoon Cancer Centre, Saskatoon, SK S7N 4H4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Branawan","family":"Gowrishankar","sequence":"additional","affiliation":[{"name":"Cross Cancer Institute, Alberta Health Services, Edmonton, AB T6G 1Z2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Hardy","sequence":"additional","affiliation":[{"name":"BC Cancer Centre, Vernon, BC V1T 5L2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mussawar","family":"Iqbal","sequence":"additional","affiliation":[{"name":"Allan Blair Cancer Centre, Regina, SK S4T 7T1, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duc","family":"Le","sequence":"additional","affiliation":[{"name":"Saskatoon Cancer Centre, Saskatoon, SK S7N 4H4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Lee-Ying","sequence":"additional","affiliation":[{"name":"Tom Baker Cancer Centre, Calgary, AB T2N 4N2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shazia","family":"Mahmood","sequence":"additional","affiliation":[{"name":"Allan Blair Cancer Centre, Regina, SK S4T 7T1, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6832-0081","authenticated-orcid":false,"given":"Karen","family":"Mulder","sequence":"additional","affiliation":[{"name":"Cross Cancer Institute, Alberta Health Services, Edmonton, AB T6G 1Z2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maged","family":"Nashed","sequence":"additional","affiliation":[{"name":"CancerCare Manitoba, Winnipeg, MB R3E 0V9, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Killian","family":"Newman","sequence":"additional","affiliation":[{"name":"Foothills Medical Centre, Calgary, AB T2N 2T9, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurice","family":"Ogaick","sequence":"additional","affiliation":[{"name":"College of Medicine, University of Saskatchewan, Saskatoon, SK S7N 5A2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vibhay","family":"Pareek","sequence":"additional","affiliation":[{"name":"CancerCare Manitoba, Winnipeg, MB R3E 0V9, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Rauw","sequence":"additional","affiliation":[{"name":"Cross Cancer Institute, Alberta Health Services, Edmonton, AB T6G 1Z2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph","family":"Wong","sequence":"additional","affiliation":[{"name":"CancerCare Manitoba, Winnipeg, MB R3E 0V9, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adnan","family":"Zaidi","sequence":"additional","affiliation":[{"name":"Saskatoon Cancer Centre, Saskatoon, SK S7N 4H4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,7,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.jhep.2021.09.007","article-title":"NAFLD-driven HCC: Safety and efficacy of current and emerging treatment options","volume":"76","author":"Foerster","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/j.hpb.2021.01.009","article-title":"Outcomes after curative therapy for hepatocellular carcinoma in patients with non-alcoholic fatty liver disease: A meta-analysis and review of current literature","volume":"23","author":"Chin","year":"2021","journal-title":"HPB"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1159\/000335713","article-title":"How much remnant is enough in liver resection?","volume":"29","author":"Guglielmi","year":"2012","journal-title":"Dig. Surg."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1097\/HEP.0000000000000466","article-title":"AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma","volume":"78","author":"Singal","year":"2023","journal-title":"Hepatology"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1002\/hep.29883","article-title":"Hepatic resection compared to chemoembolization in intermediate- to advanced-stage hepatocellular carcinoma: A meta-analysis of high-quality studies","volume":"68","author":"Hyun","year":"2018","journal-title":"Hepatology"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1097\/SLA.0000000000004346","article-title":"Overall Tumor Burden Dictates Outcomes for Patients Undergoing Resection of Multinodular Hepatocellular Carcinoma beyond the Milan Criteria","volume":"272","author":"Tsilimigras","year":"2020","journal-title":"Ann. Surg."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1002\/hep.29485","article-title":"Therapies for patients with hepatocellular carcinoma awaiting liver transplantation: A systematic review and meta-analysis","volume":"67","author":"Kulik","year":"2018","journal-title":"Hepatology"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1111\/ajt.16448","article-title":"PD-1 inhibitor as bridge therapy to liver transplantation?","volume":"21","author":"Tabrizian","year":"2021","journal-title":"Am. J. Transplant."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1007\/s40471-019-00188-3","article-title":"The Changing Epidemiology of Primary Liver Cancer","volume":"6","author":"Petrick","year":"2019","journal-title":"Curr. Epidemiol. Rep."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","article-title":"BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update","volume":"76","author":"Reig","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.jhep.2012.05.007","article-title":"A randomized controlled trial of radiofrequency ablation and surgical resection in the treatment of small hepatocellular carcinoma","volume":"57","author":"Feng","year":"2012","journal-title":"J. Hepatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1002\/bjs.10677","article-title":"Randomized clinical trial of hepatic resection versus radiofrequency ablation for early-stage hepatocellular carcinoma","volume":"104","author":"Ng","year":"2017","journal-title":"Br. J. Surg."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1159\/000521665","article-title":"Surgery versus Radiofrequency Ablation for Small Hepatocellular Carcinoma: A Randomized Controlled Trial (SURF Trial)","volume":"11","author":"Takayama","year":"2022","journal-title":"Liver Cancer"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"102526","DOI":"10.1016\/j.ctrv.2023.102526","article-title":"Clinical consensus statement: Establishing the roles of locoregional and systemic therapies for the treatment of intermediate-stage hepatocellular carcinoma in Canada","volume":"115","author":"Wong","year":"2023","journal-title":"Cancer Treat. Rev."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1148\/radiol.211806","article-title":"90Y Radioembolization versus Drug-eluting Bead Chemoembolization for Unresectable Hepatocellular Carcinoma: Results from the TRACE Phase II Randomized Controlled Trial","volume":"303","author":"Dhondt","year":"2022","journal-title":"Radiology"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"9","DOI":"10.21037\/cco-20-89","article-title":"Efficacy and safety of radiotherapy for primary liver cancer","volume":"10","author":"Chen","year":"2021","journal-title":"Chin. Clin. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"100498","DOI":"10.1016\/j.jhepr.2022.100498","article-title":"Stereotactic body radiation therapy for hepatocellular carcinoma: From infancy to ongoing maturity","volume":"4","author":"Lewis","year":"2022","journal-title":"JHEP Rep."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Kimura, T., Fujiwara, T., Kameoka, T., Adachi, Y., and Kariya, S. (2022). The Current Role of Stereotactic Body Radiation Therapy (SBRT) in Hepatocellular Carcinoma (HCC). Cancers, 14.","DOI":"10.3390\/cancers14184383"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1007\/s11864-022-01025-4","article-title":"Approach to Stereotactic Body Radiotherapy for the Treatment of Advanced Hepatocellular Carcinoma in Patients with Child-Pugh B-7 Cirrhosis","volume":"23","author":"Daniell","year":"2022","journal-title":"Curr. Treat. Options. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.3390\/curroncol30020190","article-title":"Stereotactic Body Radiotherapy for Hepatocellular Carcinoma: A Brief Overview","volume":"30","author":"Matsuo","year":"2023","journal-title":"Curr. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1002\/cld.1060","article-title":"Radiation Therapies for the Treatment of Hepatocellular Carcinoma","volume":"17","author":"Parikh","year":"2021","journal-title":"Clin. Liver. Dis."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"114","DOI":"10.3350\/cmh.2017.0073","article-title":"Strategic application of radiotherapy for hepatocellular carcinoma","volume":"24","author":"Choi","year":"2018","journal-title":"Clin. Mol. Hepatol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12962-019-0198-z","article-title":"Health economic evaluation of stereotactic body radiotherapy (SBRT) for hepatocellular carcinoma: A systematic review","volume":"18","author":"Wang","year":"2020","journal-title":"Cost. Eff. Resour. Alloc."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s13014-016-0644-4","article-title":"Cost-effectiveness of sorafenib versus SBRT for unresectable advanced hepatocellular carcinoma","volume":"11","author":"Leung","year":"2016","journal-title":"Radiat. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Wigg, A., Tibballs, J., Woodman, R., Stuart, K., Le, H., Roberts, S.K., Olynyk, J.K., Strasser, S.I., Wallace, M., and Martin, J. (2024). A randomised controlled trial of Standard Of Care versus RadioAblaTion in Early Stage HepatoCellular Carcinoma (SOCRATES HCC). BMC Cancer, 24.","DOI":"10.1186\/s12885-024-12504-2"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in Advanced Hepatocellular Carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","article-title":"Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial","volume":"10","author":"Cheng","year":"2009","journal-title":"Lancet Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: A randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_31","first-page":"EVIDoa2100070","article-title":"Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma","volume":"1","author":"Lau","year":"2022","journal-title":"NEJM Evid."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"LBA4008","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA4008","article-title":"Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line treatment for unresectable hepatocellular carcinoma (uHCC): First results from CheckMate 9DW","volume":"42","author":"Galle","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S0140-6736(24)02551-0","article-title":"Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): A multiregional, randomised, double-blind, placebo-controlled, phase 3 study","volume":"405","author":"Sangro","year":"2025","journal-title":"Lancet"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"S1229","DOI":"10.1016\/j.annonc.2024.08.2277","article-title":"LBA3 Transarterial chemoembolization (TACE) with or without lenvatinib (len) + pembrolizumab (pembro) for intermediate-stage hepatocellular carcinoma (HCC): Phase III LEAP-012 study","volume":"35","author":"Llovet","year":"2024","journal-title":"Ann. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","article-title":"Cholangiocarcinoma 2020: The next horizon in mechanisms and management","volume":"17","author":"Banales","year":"2020","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_36","first-page":"100356","article-title":"IDH inhibitors in advanced cholangiocarcinoma: Another arrow in the quiver?","volume":"27","author":"Rizzo","year":"2021","journal-title":"Cancer Treat. Res. Commun."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1002\/hep.32424","article-title":"Biology of IDH mutant cholangiocarcinoma","volume":"75","author":"Wu","year":"2022","journal-title":"Hepatology"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1073274820983013","DOI":"10.1177\/1073274820983013","article-title":"Targeting BRAF-Mutant Biliary Tract Cancer: Recent Advances and Future Challenges","volume":"27","author":"Rizzo","year":"2020","journal-title":"Cancer Control"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Ayasun, R., Ozer, M., and Sahin, I. (2023). The Role of HER2 Status in the Biliary Tract Cancers. Cancers, 15.","DOI":"10.3390\/cancers15092628"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/s41416-018-0199-2","article-title":"Mismatch repair deficiency is a rare but putative therapeutically relevant finding in non-liver fluke associated cholangiocarcinoma","volume":"120","author":"Goeppert","year":"2019","journal-title":"Br. J. Cancer"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.21037\/jgo.2019.08.08","article-title":"Patterns and genomic correlates of PD-L1 expression in patients with biliary tract cancers","volume":"10","author":"Mody","year":"2019","journal-title":"J. Gastrointest. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ejca.2021.07.045","article-title":"Role of adjuvant radiotherapy in extrahepatic bile duct cancer: A multicenter retrospective study (Korean Radiation Oncology Group 18-14)","volume":"157","author":"Kim","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Li, Q., Chen, C., Su, J., Qiu, Y., Wu, H., Song, T., Mao, X., He, Y., Cheng, Z., and Li, J. (2022). Recurrence and prognosis in intrahepatic cholangiocarcinoma patients with different etiology after radical resection: A multi-institutional study. BMC Cancer, 22.","DOI":"10.1186\/s12885-022-09448-w"},{"key":"ref_44","first-page":"100634","article-title":"Proton beam therapy for extrahepatic biliary tract cancer: Analysis with prospective multi-institutional patients\u2019 registration database, Proton-Net","volume":"41","author":"Yamazaki","year":"2023","journal-title":"Clin. Transl. Radiat. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2674","DOI":"10.1002\/cam4.2925","article-title":"Postoperative adjuvant therapy following radical resection for intrahepatic cholangiocarcinoma: A multicenter retrospective study","volume":"9","author":"Wang","year":"2020","journal-title":"Cancer Med."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Ke, Q., Lin, N., Deng, M., Wang, L., Zeng, Y., and Liu, J. (2020). The effect of adjuvant therapy for patients with intrahepatic cholangiocarcinoma after surgical resection: A systematic review and meta-analysis. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0229292"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s13014-020-1459-x","article-title":"A meta-analysis of the efficacy of postoperative adjuvant radiotherapy versus no radiotherapy for extrahepatic cholangiocarcinoma and gallbladder carcinoma","volume":"15","author":"Ren","year":"2020","journal-title":"Radiat. Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1200\/JCO.2014.60.2219","article-title":"SWOG S0809: A phase II intergroup trial of adjuvant capecitabine and gemcitabine followed by radiotherapy and concurrent capecitabine in extrahepatic cholangiocarcinoma and gallbladder carcinoma","volume":"33","author":"Guthrie","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.radonc.2020.03.017","article-title":"Prognostic factors and patterns of recurrence after curative resection for patients with distal cholangiocarcinoma","volume":"147","author":"Zhou","year":"2020","journal-title":"Radiother. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"151","DOI":"10.14701\/ahbps.22-090","article-title":"Survival analysis of extrahepatic cholangiocarcinoma based on surveillance, epidemiology, and end results database","volume":"27","author":"Ali","year":"2023","journal-title":"Ann. Hepatobiliary Pancreat. Surg."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.ijrobp.2008.10.052","article-title":"Adjuvant Therapy for Gallbladder Carcinoma: The Mayo Clinic Experience","volume":"75","author":"Gold","year":"2009","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1007\/s11605-015-2922-0","article-title":"Adjuvant Therapy for Gallbladder Cancer: An Analysis of the National Cancer Data Base","volume":"19","author":"Hoehn","year":"2015","journal-title":"J. Gastrointest. Surg."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"4627","DOI":"10.1200\/JCO.2010.33.8020","article-title":"Nomogram for predicting the benefit of adjuvant chemoradiotherapy for resected gallbladder cancer","volume":"29","author":"Wang","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1200\/JCO.2011.40.5381","article-title":"Adjuvant therapy in the treatment of biliary tract cancer: A systematic review and meta-analysis","volume":"30","author":"Horgan","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/S2468-1253(24)00095-5","article-title":"Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): Updated overall survival from a randomised phase 3 study","volume":"9","author":"Oh","year":"2024","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Kelley","year":"2023","journal-title":"Lancet"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/S1470-2045(21)00027-9","article-title":"Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): A phase 3, open-label, randomised, controlled trial","volume":"22","author":"Lamarca","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/bjc.2016.446","article-title":"Efficacy of fluoropyrimidine-based chemotherapy in patients with advanced biliary tract cancer after failure of gemcitabine plus cisplatin: Retrospective analysis of 321 patients","volume":"116","author":"Kim","year":"2017","journal-title":"Br. J. Cancer."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1016\/S1470-2045(21)00486-1","article-title":"Liposomal irinotecan plus fluorouracil and leucovorin versus fluorouracil and leucovorin for metastatic biliary tract cancer after progression on gemcitabine plus cisplatin (NIFTY): A multicentre, open-label, randomised, phase 2b study","volume":"22","author":"Yoo","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"E615","DOI":"10.1503\/cmaj.240095","article-title":"Projected estimates of cancer in Canada in 2024","volume":"196","author":"Brenner","year":"2024","journal-title":"Can. Med. Assoc. J."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/j.annonc.2020.07.014","article-title":"Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: A report from the ESMO Precision Medicine Working Group","volume":"31","author":"Mosele","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","article-title":"Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: A multicentre, open-label, phase 2 study","volume":"21","author":"Sahai","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"S376","DOI":"10.1016\/j.annonc.2021.08.326","article-title":"47P Derazantinib for patients with intrahepatic cholangiocarcinoma harboring FGFR2 fusions\/rearrangements: Primary results from the phase II study FIDES-01","volume":"32","author":"Busset","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S1470-2045(23)00275-9","article-title":"Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): An international, single-arm, phase 2 study","volume":"24","author":"Pant","year":"2023","journal-title":"Lancet Oncol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa2206834","article-title":"Futibatinib for FGFR2 -Rearranged Intrahepatic Cholangiocarcinoma","volume":"388","author":"Goyal","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S2468-1253(21)00196-5","article-title":"Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: Mature results from a multicentre, open-label, single-arm, phase 2 study","volume":"6","author":"Javle","year":"2021","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"S1381","DOI":"10.1016\/j.annonc.2022.08.006","article-title":"LBA12 Efficacy of RLY-4008, a highly selective FGFR2 inhibitor in patients (pts) with an FGFR2-fusion or rearrangement (f\/r), FGFR inhibitor (FGFRi)-na\u00efve cholangiocarcinoma (CCA): ReFocus trial","volume":"33","author":"Hollebecque","year":"2022","journal-title":"Ann. Oncol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S1470-2045(20)30157-1","article-title":"Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): A multicentre, randomised, double-blind, placebo-controlled, phase 3 study","volume":"21","author":"Macarulla","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1001\/jamaoncol.2021.3836","article-title":"Final Overall Survival Efficacy Results of Ivosidenib for Patients with Advanced Cholangiocarcinoma with IDH1 Mutation: The Phase 3 Randomized Clinical ClarIDHy Trial","volume":"7","author":"Zhu","year":"2021","journal-title":"JAMA Oncol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1056\/NEJMoa1714448","article-title":"Efficacy of Larotrectinib in TRK Fusion\u2013Positive Cancers in Adults and Children","volume":"378","author":"Drilon","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1470-2045(19)30691-6","article-title":"Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: Integrated analysis of three phase 1\u20132 trials","volume":"21","author":"Doebele","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"3228","DOI":"10.1200\/JCO.23.02078","article-title":"Pertuzumab Plus Trastuzumab in Patients With Biliary Tract Cancer With ERBB2\/3 Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study","volume":"42","author":"Cannon","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1016\/S1470-2045(21)00336-3","article-title":"Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): A multicentre, open-label, phase 2a, multiple basket study","volume":"22","author":"Javle","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"5569","DOI":"10.1200\/JCO.23.00606","article-title":"Tucatinib and Trastuzumab for Previously Treated Human Epidermal Growth Factor Receptor 2-Positive Metastatic Biliary Tract Cancer (SGNTUC-019): A Phase II Basket Study","volume":"41","author":"Nakamura","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/S1470-2045(24)00140-2","article-title":"Trastuzumab deruxtecan in patients with solid tumours harbouring specific activating HER2 mutations (DESTINY-PanTumor01): An international, phase 2 study","volume":"25","author":"Li","year":"2024","journal-title":"Lancet Oncol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"3207","DOI":"10.1200\/JCO.23.02010","article-title":"Trastuzumab Deruxtecan in Human Epidermal Growth Factor Receptor 2-Expressing Biliary Tract Cancer (HERB; NCCH1805): A Multicenter, Single-Arm, Phase II Trial","volume":"42","author":"Ohba","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/S1470-2045(23)00242-5","article-title":"Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): A multicentre, single-arm, phase 2b study","volume":"24","author":"Harding","year":"2023","journal-title":"Lancet Oncol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1917239","article-title":"KRAS G12C Inhibition with Sotorasib in Advanced Solid Tumors","volume":"383","author":"Hong","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"4097","DOI":"10.1200\/JCO.23.00434","article-title":"Adagrasib in Advanced Solid Tumors Harboring a KRAS G12CMutation","volume":"41","author":"Yaeger","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"3895","DOI":"10.1200\/JCO.20.00762","article-title":"Dabrafenib and trametinib in patients with tumors with BRAFV600E mutations: Results of the NCI-MATCH trial subprotocol H","volume":"38","author":"Salama","year":"2020","journal-title":"J. Clin. Oncol."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/32\/7\/398\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:07:51Z","timestamp":1760033271000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/32\/7\/398"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,10]]},"references-count":81,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["curroncol32070398"],"URL":"https:\/\/doi.org\/10.3390\/curroncol32070398","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,10]]}}}